The goal in developing BioDMET is to create a tool general enough to solve a broad range of problems while at the same time remain easy-to-use by biologists, chemists, and modelers.
A well-tested PBPK model can be used by scientists to make better decisions during most stages of pharmaceutical research and development (R&D). Doing so has the potential to improve productivity and lower R&D costs.
The features of BioDMET currently include:
- Detailed whole-body physiological PBPK models (down to the sub-cellular levels) for
- Possibility of user-implemented changes for age, body weight, gender, health condition.
- Possibility to further refine the model structure by adding new cell types or receptors to the models.
- Database of pre-built pathogen models that can be further customized.
- Validation datasets and test cases consisting of calculated biodistribution data for a number of agents in various tissues and organs compared to published experimental values.
- Wizard-assisted setup - to guide the user through the process of setting up a simulation either by combining existing elements from the model database or from scratch.
- No programming skills needed to build new models and run calculations.
- The "history of changes" to BioDMET is now available.
- Calculating drug dosing.
- Calculating the distribution of drugs within host tissues, cells, and fluid spaces.
- Modeling antibiotic and
antiviral pathogen/drug interactions.
- Modeling impact of disease and infection on the pharmacokinetics.
- Analyzing the impact of physiology changes of the critically-ill on the pharmacokinetics.
- Simulate the in vivo animal to help guide the design of animal experiments.
- Help test a working hypothesis or interpretation of an experimental observation (Does the calculations match the experimental result?)
Biomedical Imaging Agent Development
- Assess feasibility of imaging from a systems perspective that includes:
- binding rates
- acquisition time
- Help prioritize lists of potential biomarker and imaging agent molecules according to their likelihood of providing the highest degree of sensitivity to the disease state and its progression.
- Identify the required molecular biomarker and imaging agent properties, specific for the given disease application and imaging modality.
- Provide understanding and insight for mechanisms and facilitate hypothesis generation.
Copyright © 2009-2013 General Electric Corp. All rights reserved.
|Model and tool development funded by GE and
Defense Threat Reduction Agency Contract No. HDTRA-08-C-0052